Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma - 11/09/11
Abstract |
Background: A new anticancer therapy, electrochemotherapy (ECT), has been introduced that entails exposing cancerous tissues to short pulses of electricity during chemotherapy. This enhances cell membrane permeability and has been shown to have potent antitumor effects in vitro in animal models and in several clinical trials, including nevoid basal cell carcinoma (BCC). Objective: We report the effects of ECT on 20 patients with primary BCC. Methods: Electrical pulses were delivered to 54 tumors after administration of intralesional bleomycin sulfate. Results: Complete responses were observed in 53 (98%), and in the majority of these (94%) after a single treatment. No recurrences have been recorded with a mean of 18 months of observation. Conclusion: Although these are preliminary results, ECT appears to be an effective alternative to surgical excision for the treatment of primary BCC. (J Am Acad Dermatol 1997;37:596-9.)
Le texte complet de cet article est disponible en PDF.Plan
Supported by a grant from Genetronics, Inc., San Diego, Calif. |
|
Reprint requests: Frank Glass, MD, Assistant Professor of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., Box 19, Tampa, FL 33612. |
|
0190-9622/97/$5.00 + 0 16/1/83590 |
Vol 37 - N° 4
P. 596-599 - octobre 1997 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?